Apolipoprotein E genotype is not associated with cognitive impairment in older adults with bipolar disorder

Bipolar Disorders

Volumn 18, Issue 1, 2016, Pages 71-77

  Kerr, Daniel Shikanai ^a   Stella, Florindo ^a,b   Radanovic, Márcia ^a   Aprahamian, Ivan ^a   Bertollucci, Paulo Henrique Ferreira ^c   Forlenza, Orestes Vicente ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

APOE; 4; Alzheimer's disease; Apolipoprotein E; Bipolar disorder; Cognitive decline; Mild cognitive impairment

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E4;

ADULT; ALLELE; ALZHEIMER DISEASE; APOE GENE; APOE2 GENE; APOE4 GENE; ARTICLE; BIPOLAR DISORDER; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTOR; AGED; COMPLICATION; GENETIC PREDISPOSITION; GENETICS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BIPOLAR DISORDER; COGNITION DISORDERS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; REAL-TIME POLYMERASE CHAIN REACTION; RISK FACTORS;

EID: 84958647258     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12367     Document Type: Article

References (57)

1. Tsai S-Y, Lee H-C, Chen C-C, Huang Y-L. Cognitive impairment in later life in patients with early-onset bipolar disorder. Bipolar Disord 2007; 9: 868-875.
2. Aprahamian I, Ladeira RB, Diniz BS, Forlenza OV, Nunes PV. Cognitive impairment in euthymic older adults with bipolar disorder: a controlled study using cognitive screening tests. Am J Geriatr Psychiatry 2014; 22: 389-397.
3. Forlenza OV, Aprahamian I. Cognitive impairment and dementia in bipolar disorder. Front Biosci (Elite Ed) 2013; 5: 258-265.
4. Samamé C, Martino DJ, Strejilevich SA. A quantitative review of neurocognition in euthymic late-life bipolar disorder. Bipolar Disord 2013; 15: 633-644.
5. Hartberg CB, Sundet K, Rimol LM et al. Subcortical brain volumes relate to neurocognition in schizophrenia and bipolar disorder and healthy controls. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1122-1130.
6. Serafini G, Pompili M, Innamorati M et al. Deep white matter hyperintensities as possible predictor of poor prognosis in a sample of patients with late-onset bipolar II disorder. Bipolar Disord 2010; 12: 755-756.
7. Kieseppä T, Mäntylä R, Tuulio-Henriksson A et al. White matter hyperintensities and cognitive performance in adult patients with bipolar I, bipolar II, and major depressive disorders. Eur Psychiatry 2014; 29: 226-232.
8. Beyer JL, Kuchibhatla M, Payne ME et al. Gray and white matter brain volumes in older adults with bipolar disorder. Int J Geriatr Psychiatry 2009; 24: 1445-1452.
9. Ekman CJ, Lind J, Rydén E, Ingvar M, Landén M. Manic episodes are associated with grey matter volume reduction - a voxel-based morphometry brain analysis. Acta Psychiatr Scand 2010; 122: 507-515.
10. Brambilla P, Harenski K, Nicoletti M et al. Differential effects of age on brain gray matter in bipolar patients and healthy individuals. Neuropsychobiology 2001; 43: 242-247.
11. Aprahamian I, Radanovic M, Nunes PV, Ladeira RB, Forlenza OV. The use of the Clock Drawing Test in bipolar disorder with or without dementia of Alzheimer's type. Arq Neuropsiquiatr 2014; 72: 913-918.
12. Radanovic M, Nunes PV, Forlenza OV, Braga LR, Gattaz WF. Cognitive-linguistic deficits in euthymic elderly patients with bipolar disorder. J Affect Disord 2013; 150: 691-694.
13. Delaloye C, Moy G, Baudois S et al. Cognitive features in euthymic bipolar patients in old age. Bipolar Disord 2009; 11: 735-743.
14. Depp CA, Savla GN, Moore DJ et al. Short-term course of neuropsychological abilities in middle-aged and older adults with bipolar disorder. Bipolar Disord 2008; 10: 684-690.
15. Dubois B, Feldman HH, Jacova C et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 2014; 13: 614-629.
16. Forlenza OV, Diniz BS, Gattaz WF. Diagnosis and biomarkers of predementia in Alzheimer's disease. BMC Med 2010; 8: 89.
17. Van Harten AC, Visser PJ, Pijnenburg YA et al. Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimer's Dement 2013; 9: 481-487.
18. Nunes PV, Forlenza OV, Gattaz WF. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry 2007; 190: 359-360.
19. Rolstad S, Jakobsson J, Sellgren C et al. Cognitive performance and cerebrospinal fluid biomarkers of neurodegeneration: a study of patients with bipolar disorder and healthy controls. PLoS ONE 2015; 10: e0127100.
20. Martínez-Arán A, Vieta E, Colom F et al. Cognitive dysfunctions in bipolar disorder: evidence of neuropsychological disturbances. Psychother Psychosom 2000; 69: 2-18.
21. Gatt JM, Burton KLO, Williams LM, Schofield PR. Specific and common genes implicated across major mental disorders: a review of meta-analysis studies. J Psychiatr Res 2015; 60: 1-13.
22. Vila-Rodriguez F, Honer WG, Innis SM, Wellington CL, Beasley CL. ApoE and cholesterol in schizophrenia and bipolar disorder: comparison of grey and white matter and relation with APOE genotype. J Psychiatry Neurosci 2011; 36: 47-55.
23. Holtzman DM, Herz J, Bu G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2: a006312.
24. Genin E, Hannequin D, Wallon D et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry 2011; 16: 903-907.
25. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci USA 2006; 103: 5644-5651.
26. Gibbons AS, Udawela M, Jeon WJ et al. The neurobiology of APOE in schizophrenia and mood disorders. Front Biosci 2011; 16: 962-979.
27. Butters MA, Sweet RA, Mulsant BH et al. APOE is associated with age-of-onset, but not cognitive functioning, in late-life depression. Int J Geriatr Psychiatry 2003; 18: 1075-1081.
28. Qiu WQ, Zhu H, Dean M et al. Amyloid-associated depression and ApoE4 allele: longitudinal follow-up for the development of Alzheimer's disease. Int J Geriatr Psychiatry 2015. doi:10.1002/gps.4339.
29. Chung JK, Plitman E, Nakajima S et al. Lifetime history of depression predicts increased amyloid-β accumulation in patients with mild cognitive impairment. J Alzheimers Dis 2015; 45: 907-919.
30. Soeira-de-Souza MG, Soeiro de Souza MG, Bio DS et al. Apolipoprotein E genotype and cognition in bipolar disorder. CNS Neurosci Ther 2010; 16: 316-321.
31. Steffens DC, Plassman BL, Helms MJ et al. A twin study of late-onset depression and apolipoprotein E epsilon 4 as risk factors for Alzheimer's disease. Biol Psychiatry 1997; 41: 851-856.
32. Kessing LV, Jørgensen OS. Apolipoprotein E-epsilon 4 frequency in affective disorder. Biol Psychiatry 1999; 45: 430-434.
33. Zubenko GS, Henderson R, Stiffler JS et al. Association of the APOE epsilon 4 allele with clinical subtypes of late life depression. Biol Psychiatry 1996; 40: 1008-1016.
34. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC:American Psychiatric Association, 2000.
35. McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
36. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256: 183-194.
37. Brucki SMD, Nitrini R, Caramelli P, Bertolucci PHF, Okamoto IH. Suggestions for utilization of the mini-mental state examination in Brazil. Arq Neuropsiquiatr 2003; 61: 777-781.
38. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
39. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-435.
40. Laitinen J, Samarut J, Holtta E. A nontoxic and versatile protein salting-out method for isolation of DNA. Biotechniques 1994; 17: 316, 318, 320-322.
41. Forlenza OV, Diniz BS, Talib LL et al. Clinical and biological predictors of Alzheimer's disease in patients with amnestic mild cognitive impairment. Rev Bras Psiquiatr 2010; 32: 216-222.
42. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 2007; 39: 17-23.
43. Bellivier F, Laplanche JL, Schürhoff F et al. Apolipoprotein E gene polymorphism in early and late onset bipolar patients. Neurosci Lett 1997; 233: 45-48.
44. Robinson LJ, Thompson JM, Gallagher P et al. A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. J Affect Disord 2006; 93: 105-115.
45. Mosconi L, Perani D, Sorbi S et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 2004; 63: 2332-2340.
46. Shi J, Han P, Kuniyoshi SM. Cognitive impairment in neurological diseases: lessons from apolipoprotein E. J Alzheimers Dis 2014; 38: 1-9.
47. Jack CR, Knopman DS, Jagust WJ et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013; 12: 207-216.
48. Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol 2011; 10: 241-252.
49. Schouws SNTM, Stek ML, Comijs HC, Beekman ATF. Risk factors for cognitive impairment in elderly bipolar patients. J Affect Disord 2010; 125: 330-335.
50. Forlenza OV, Diniz BS, Nunes PV et al. Diagnostic transitions in mild cognitive impairment subtypes. Int Psychogeriatr 2009; 21: 1088-1095.
51. Braak H, Braak E, Bohl J. Staging of Alzheimer-related cortical destruction. Eur Neurol 1993; 33: 403-408.
52. Jakobsson J, Zetterberg H, Blennow K et al. Altered concentrations of amyloid precursor protein metabolites in the cerebrospinal fluid of patients with bipolar disorder. Neuropsychopharmacology 2013; 38: 664-672.
53. Balanzá-Martínez V, Tabarés-Seisdedos R, Selva-Vera G et al. Persistent cognitive dysfunctions in bipolar I disorder and schizophrenic patients: a 3-year follow-up study. Psychother Psychosom 2005; 74: 113-119.
54. Gildengers AG, Mulsant BH, Begley A et al. The longitudinal course of cognition in older adults with bipolar disorder. Bipolar Disord 2009; 11: 744-752.
55. Moorhead TWJ, McKirdy J, Sussmann JED et al. Progressive gray matter loss in patients with bipolar disorder. Biol Psychiatry 2007; 62: 894-900.
56. Mur M, Portella MJ, Martínez-Arán A, Pifarré J, Vieta E. Long-term stability of cognitive impairment in bipolar disorder: a 2-year follow-up study of lithium-treated euthymic bipolar patients. J Clin Psychiatry 2008; 69: 712-719.
57. Pena SDJ, Di Pietro G, Fuchshuber-Moraes M et al. The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected. PLoS ONE 2011; 6: e17063.